23 results about "Dopaminergic Agonists" patented technology

Sublingual compositions for the treatment of erectile dysfunction (ED) comprise unique combinations of phosphodiesterase-type 5 (PDE5) inhibitors and D1 / D2 dopamine receptor agonists. In preferred embodiments, a combination of four drug actives exhibits a full range of effectiveness for ED in which there is a short and long acting PDE5 inhibitor in combination with both a dopamine agonist and a CNS hormone to provide both a physiological response and a psychological / CNS action. A treatment for ED comprises administration of sublingual compositions in the physical form of sublingual tablets.

The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in treating conditions for which treatment with a dopamine agonist has therapeutic benefit, and pharmaceutical compositions comprising a compound of the present invention. The compounds according to the present invention have the formula (Id), wherein R1and R2are each independently selected from H and the substituent (iii) below, wherein * indicates the point of attachment to oxygen, wherein R3is selected from H and COR4, and wherein R4is selected from H and C1-C6alkyl, with the proviso that R1and R2cannot both be H, 15or a pharmaceutically acceptable salt thereof.

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

Compositions and methods for treating neurological conditions are provided. The present invention provides a pharmaceutical composition comprising a dopamine reuptake inhibitor or dopamine agonist, an adrenergic receptor antagonist, and a pharmaceutically acceptable carrier, and a method for treating a neurological disorder by administering the composition.

The present invention relates to methods and devices for providing a treatment recommendation based on a prediction of at least one Impulse Control Disorder occurrence for a patient undergoing a treatment with Dopamine Agonists.

To provide a method and a composition for treating falling-related symptoms in a patient having a neurodegenerative disease such as Parkinson disease or a Parkinson disease-related disease.SOLUTION: In some embodiments, by using nicotine or a salt thereof in combination with dopamine agonist treatment, falling-related symptoms are reduced such as reducing frequency of falling, reducing injury related with falling, reducing seriousness of injury related with falling, improving freezing of gait, improving posture stability, improving kinetic force, and improving balance and walking, In some embodiments, the method predicts frequency of falling and tendency of falling recurrence in a patient having Parkinson disease, more specifically, a patient having general Parkinson disease.SELECTED DRAWING: Figure 3

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

1. The name of the design product: long handle hair stick (Dopamine). 2. The use of the design product: for hair stick. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and / or a growth hormone receptor antagonist and / or a selective estrogen receptor modulator (SERM) and / or a 2nd somatostatin receptor ligand (SRL).

This invention discloses a novel method for detecting isomer impurities in dopamine agonists. The method employs high-performance liquid chromatography (HPLC), using a cyclodextrin-packed column, with sodium perchlorate buffer as mobile phase A and acetonitrile as mobile phase B. The test solution is injected into the HPLC system for isocratic elution. This invention overcomes the technical bias of requiring forward chromatography for isomer detection and separation, creatively exploring a method for analyzing and detecting isomer impurities in pramipexole hydrochloride tablets using reverse chromatography. The method offers advantages such as high specificity, high accuracy, good durability, and low reagent hazard, effectively filling a gap in the quality standards for pramipexole hydrochloride tablets. It provides a technical reference for the quality control of pramipexole hydrochloride tablets, ensuring medication safety.

The invention provides a novel pharmaceutical composition comprising a phosphodiesterase type 5 (PDE5) inhibitor other than sildenafil and a dopamine agonist and method of use thereof for treating erectile dysfunction and / or male hypogonadism.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.

The invention relates to the technical field of yang tonifying, and discloses a hippocampus and pilose antler essence health-care paste which mainly comprises 30 g of actinolite, 30 g of morinda officinalis, 5 g of pilose antler, 5 g of hippocampus, 30 g of radix cyathulae, 50 g of herba epimedii, 15 g of cynomorium songaricum, 15 g of eucommia ulmoides, 15 g of semen cuscutae, 30 g of schisandra chinensis, 30 g of ligusticum wallichii, 30 g of cinnamon, 15 g of ginger, 50 g of cistanche, 30 g of salvia miltiorrhiza, 30 g of clove, 30 g of fructus cnidii, 50 g of radix polygoni multiflori preparata, 15 g of rhizoma polygonati and 30 g of rhizoma acori graminei Compared with other products in the market, the health-care wine does not contain nafil, ramine, caine and oxetine drugs, also contains the components such as a phosphodiesterase (PDE5) inhibitor, an adrenergic receptor blocker, a dopamine agonist, an anesthetic and capsaicin, does not cause damage to the body after being drunk, does not affect the effect, and is safe and reliable. Adverse reactions such as dizziness, headache, abdominal distension, nausea, persistent excitation, sexual overdraft and the like are not generated.

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson’s disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

A pharmaceutical composition containing a dopamine reuptake inhibitor or a dopaminergic agonist, an adrenergic receptor antagonist and a pharmaceutically acceptable carrier, and a method for treating neurological diseases by administering the composition.

The invention relates to dopamine, a dopamine agonist, L-DOPA or a prodrug thereof for use in a method for the treatment of dopamine deficiency in a subject characterized in that the treatment of the deficiency further comprises the administration of tadalafil or variant thereof to the subject. The combination with tadalafil or variant thereof allows a reduction in the amount of dopamine, a dopamine agonist, L-DOPA or a prodrug thereof resulting in reduced extrastriatal side effects. The disclosure further relates to compositions, medicaments and kits of parts comprising dopamine, a dopamine agonist, L-DOPA or a prodrug thereof and tadalafil, optionally further comprising a PDE11 inhibitor, a PDE2 inhibitor, a guanyl cyclase agonist, or a combination thereof.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The present invention relates to the use of nicotinic acetylcholine receptor alpha 7 activators, in particular to the use of nicotinic acetylcholine receptor alpha 7 agonists for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's disease.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

Disclosed are compositions comprising 0.1-50% delta-9-tetrahydrocannabinol and / or cannabidiol in a form suitable for continuous delivery, and their use in the treatment of various diseases and pathological disorders. In preferred embodiments, the compositions are in a form suitable for delivery via a portable infusion pump or transdermal patch. Disorders to be treated include pain, cancer, seizure disorders, and Parkinson's disease. Depending on the disorder being treated, the compositions may optionally further comprise an additional active agent, for example, a dopamine agonist.